Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

UK-based GW Pharmaceuticals nets $29mm in US IPO

Executive Summary

GW Pharmaceuticals PLC, UK developer of prescription cannabinoids, netted $29mm in its initial public offering in the US on the Nasdaq. As planned, it sold 3.5mm ADSs for $8.90. The company has been trading publicly on the London Stock Exchange’s AIM since June 2001.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies